Hepatitis C impacts an estimated 3.2 million Americans. Between 60 and 70% of those with hepatitis C develop chronic liver disease, between 5 and 20% will eventually develop cirrhosis, and an estimated 12,000 die from hepatitis C related illness each year.
Most Recent Posts
China’s Food and Drug Administration recently issued a warning to patients that it cannot guarantee the safety, authenticity and efficacy of cancer medicines purchased online. The new warning was issued after a study by drug regulators in Shenzhen found that 75 percent of foreign cancer medicines purchased online were found to be counterfeit or ineffective.
Yesterday, stakeholders had an opportunity to meet with and present to negotiators participating in the fifth round of Transatlantic Trade and Investment Partnership (TTIP) talks taking place in Arlington, Virginia.
The Atlantic today led a discussion around the value and cost of innovative medicines. This is an important topic and one that all partners in the U.S. health care system must continue to discuss. Most importantly, patient voices need to be a part of any discussion around the value of innovative medicines. As this debate moves forward, here are some additional facts that need to be a part of the discussion.
President Obama has proclaimed this week “World Trade Week” to raise awareness about the importance of expanding the U.S. international trade footprint in order to generate jobs.
While today is International Clinical Trials Day, at PhRMA we recognize the groundbreaking advances in medicine made possible by clinical trials and the critical contribution of the patients who volunteer in clinical trials every day.
Last week, after an election process that took more than a month to complete with a record 550 million votes cast, the Indian people elected a new Prime Minister in a landslide election that unseated the country’s ruling Congress party. Narendra Modi and the Bharatiya Janata Party (BJP) won enough seats in the lower house of Parliament to form a government.
Our member companies strive every day to bring innovative new medicines and treatments into the market to improve the lives of patients, both in the United States and abroad. Access to high-quality medicines is our common goal and top priority. Unfortunately, some health plans now being offered make it more difficult for people to get access to the medicines they need.
There have been a lot of discussions lately about the value and cost of cancer medicines – it is also an issue that will be raised at the upcoming American Society of Clinical Oncology’s (ASCO) annual meeting.
Biopharmaceutical innovators work every day to build a robust pipeline and develop new medicines that help patients cope with some of the most debilitating diseases. This week, we released a new Medicines in Development report on mental health disorders that discussed a number of new approaches being pursued in order to treat these conditions. Currently, an estimated 61.5 million Americans suffer from mental illness, or one in every four U.S.
So often the value of medicines gets lost in media reports when the focus is almost exclusively on cost.
Are we as a society willing to accept the fact that medicines, while not always inexpensive, provide great return on value because a child’s life has been saved or a friend was able to beat cancer?
Each year at the National Prescription Drug Abuse Summit, discussions take place regarding the latest resources and tools for states, pharmacists, physicians, and law enforcement to use in combating the misuse and abuse of prescription medicines.
Yesterday’s release of the Special 301 report by the Office of the United States Trade Representative (USTR) once again underscores the challenges faced by innovators when confronted with deteriorating protections for intellectual property across the globe.